Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 17/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 17/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7803702 | 0.85 | CCR1 (0.38) | CCR1HCRTR1HCRTR2KCNH2 | |
| SCHEMBL20436477 | 0.84 | CCR1 (0.36) | CCR1HCRTR1HCRTR2KCNH2 | |
| SCHEMBL20436470 | 0.84 | CCR1 (0.36) | CCR1HCRTR1HCRTR2KCNH2 | |
| SCHEMBL30382126 | 0.83 | HCRTR1 (0.42) | CCR1HCRTR1HCRTR2 | |
| SCHEMBL536688 | 0.83 | HCRTR1 (0.42) | CCR1HCRTR1HCRTR2 | |
| SCHEMBL2440105 | 0.81 | CCR1 (0.40) | CCR1HCRTR1HCRTR2KCNH2 | |
| SCHEMBL24915287 | 0.78 | CCR1 (0.38) | CCR1HCRTR1HCRTR2 | |
| SCHEMBL21790630 | 0.77 | ADORA2A (0.42) | CCR1HCRTR1HCRTR2 | |
| SCHEMBL25543526 | 0.77 | ADORA2A (0.42) | CCR1HCRTR1HCRTR2 | |
| SCHEMBL23364941 | 0.76 | HTR7 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| EP-4122927-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (CN) | 2023-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | ADORA2A, ADORA2B, ADORA3 | CCR1 1981/4885HCRTR1 1495/4885HCRTR2 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.